Tibet Pharmaceutical announced that revenue for the semi-year 2026 was 1,554 billion yuan, down 5.83% year on year; net profit attributable to shareholders of listed companies was 608 million yuan, up 7.16% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 440 million yuan, down 19.00% year on year. The company plans to distribute a cash dividend of 1.15 yuan per share to all shareholders based on the total share capital after deducting the repurchase of special account shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.